The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Diosgenin targets Akt‐mediated prosurvival signaling in human breast cancer cells
Abstract
In recent years, Akt signaling has gained recognition for its functional role in more aggressive, therapy‐resistant malignancies. As it is frequently constitutively active in cancer cells, several drugs are being investigated for their ability to inhibit Akt signaling. The purpose of this study is to determine effect of diosgenin (fenugreek), a dietary compound on Akt signaling and its downstream targets on estrogen receptor positive (ER+) and estrogen receptor negative (ER−) breast cancer (BCa) cells. Diosgenin inhibits pAkt expression and Akt kinase activity without affecting PI3 kinase levels, resulting in the inhibition of its downstream targets, NF‐κB, Bcl‐2, survivin and XIAP. The Raf/MEK/ERK pathway, another functional downstream target of Akt, was inhibited by diosgenin in ER+ but not in ER− BCa cells. Additionally, we found that diosgenin caused G1 cell cycle arrest by downregulating cyclin D1, cdk‐2 and cdk‐4 expression in both ER+ and ER− BCa cells resulting in the inhibition of cell proliferation and induction of apoptosis. Interestingly, no significant toxicity was seen in the normal breast epithelial cells (MCF‐10A) following treatment with diosgenin. Additionally, in vivo tumor studies indicate diosgenin significantly inhibits tumor growth in both MCF‐7 and MDA‐231 xenografts in nude mice. Thus, these results suggest that diosgenin might prove to be a potential chemotherapeutic agent for the treatment of BCa. © 2009 UICC
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GSK-3: tricks of the trade for a multi-tasking kinase
Doble, B. W., & Woodgett, J. R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00384 · Cited by 2,084
Cited by
Saponins as cytotoxic agents: a review
Podolak, I., Galanty, A., & Sobolewska, D. (2010) · Phytochemistry Reviews · doi:10.1007/s11101-010-9183-z · Cited by 704
Targeting inflammatory pathways by triterpenoids for prevention and treatment of cancer.
Yadav, V. R., Prasad, S., Sung, B., Kannappan, R., & Aggarwal, B. B. (2010) · Toxins · doi:10.3390/toxins2102428 · Cited by 320
Diosgenin: Recent Highlights on Pharmacology and Analytical Methodology
Jesus, M., Martins, A. P. J., Gallardo, E., & Silvestre, S. (2016) · Journal of Analytical Methods in Chemistry · doi:10.1155/2016/4156293 · Cited by 273
Pro-Apoptotic and Anti-Cancer Properties of Diosgenin: A Comprehensive and Critical Review
Sethi, G., Shanmugam, M., Warrier, S., Merarchi, M., Arfuso, F., Kumar, A., & Bishayee, A. (2018) · Nutrients · doi:10.3390/nu10050645 · Cited by 253
Diosgenin: An Updated Pharmacological Review and Therapeutic Perspectives
Semwal, P., Painuli, S., Abu-Izneid, T., Rauf, A., Sharma, A., Daştan, S. D., Kumar, M., Alshehri, M. M., Taheri, Y., Das, R., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/1035441 · Cited by 195
Parama, D., Boruah, M., Yachna, K., Rana, V., Banik, K., Harsha, C., Thakur, K. K., Dutta, U., Arya, A., Mao, X., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118182 · Cited by 155
Role of dietary bioactive natural products in estrogen receptor-positive breast cancer
Bak, M. J., Das Gupta, S., Wahler, J., & Suh, N. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.03.001 · Cited by 80
Metadata
- Authors
- Srinivasan, S., Koduru, S., Kumar, R., Venguswamy, G., Kyprianou, N., & Damodaran, C.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2009-06-11
- Volume
- 125
- Issue
- 4
- Pages
- 961-967
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2036453394
- Cited by
- 158
- References
- 1
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.